MD3713919T2 - Forme cristaline de N-(4-(4-(ciclopropilmetil)piperazin-1-carbonil)fenil)chinolin-8-sulfonamidă - Google Patents

Forme cristaline de N-(4-(4-(ciclopropilmetil)piperazin-1-carbonil)fenil)chinolin-8-sulfonamidă

Info

Publication number
MD3713919T2
MD3713919T2 MDE20200988T MDE20200988T MD3713919T2 MD 3713919 T2 MD3713919 T2 MD 3713919T2 MD E20200988 T MDE20200988 T MD E20200988T MD E20200988 T MDE20200988 T MD E20200988T MD 3713919 T2 MD3713919 T2 MD 3713919T2
Authority
MD
Moldova
Prior art keywords
cyclopropylmethyl
sulfonamide
quinoline
piperazine
carbonyl
Prior art date
Application number
MDE20200988T
Other languages
English (en)
Inventor
Jacob P Sizemore
Liting Guo
Mahmoud Mirmehrabi
Yeqing Su
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MD3713919T2 publication Critical patent/MD3713919T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

În acest document sunt furnizate forme de sare hemisulfat amorfe şi cristaline cu formula:Sunt de asemenea furnizate compoziţii farmaceutice cuprizând formele de sare hemisulfat amorfe şi cristaline, metode pentru producerea acestora, şi utilizări ale acestora pentru tratarea afecţiunilor asociate cu piruvat kinaza cum ar fi deficienţa de piruvat kinază.
MDE20200988T 2017-11-22 2018-11-21 Forme cristaline de N-(4-(4-(ciclopropilmetil)piperazin-1-carbonil)fenil)chinolin-8-sulfonamidă MD3713919T2 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589822P 2017-11-22 2017-11-22
US201862691709P 2018-06-29 2018-06-29
PCT/US2018/062197 WO2019104134A1 (en) 2017-11-22 2018-11-21 Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Publications (1)

Publication Number Publication Date
MD3713919T2 true MD3713919T2 (ro) 2024-02-29

Family

ID=64734113

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20200988T MD3713919T2 (ro) 2017-11-22 2018-11-21 Forme cristaline de N-(4-(4-(ciclopropilmetil)piperazin-1-carbonil)fenil)chinolin-8-sulfonamidă

Country Status (26)

Country Link
US (2) US11254652B2 (ro)
EP (2) EP4285904A3 (ro)
JP (2) JP7275130B2 (ro)
KR (1) KR20200090787A (ro)
CN (2) CN117551030A (ro)
AU (2) AU2018373122B2 (ro)
BR (1) BR112020010185A2 (ro)
CA (1) CA3081945A1 (ro)
DK (1) DK3713919T3 (ro)
ES (1) ES2959764T3 (ro)
FI (1) FI3713919T3 (ro)
HR (1) HRP20230931T1 (ro)
HU (1) HUE063264T2 (ro)
IL (2) IL274488B2 (ro)
LT (1) LT3713919T (ro)
MD (1) MD3713919T2 (ro)
MX (2) MX2020005348A (ro)
PH (1) PH12020550644A1 (ro)
PL (1) PL3713919T3 (ro)
PT (1) PT3713919T (ro)
RS (1) RS64592B1 (ro)
SG (1) SG11202004587XA (ro)
SI (1) SI3713919T1 (ro)
TW (2) TWI808108B (ro)
UA (1) UA127502C2 (ro)
WO (1) WO2019104134A1 (ro)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3241554B1 (en) * 2009-06-29 2020-01-29 Agios Pharmaceuticals, Inc. Quinoline-8-sulfonamide derivatives having an anticancer activity
TW202244048A (zh) 2017-03-20 2022-11-16 美商佛瑪治療公司 作為丙酮酸激酶（ｐｋｒ）活化劑之吡咯并吡咯組成物
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
US20230055923A1 (en) 2018-09-19 2023-02-23 Forma Therapeutics, Inc. Activating pyruvate kinase r
CA3145138A1 (en) * 2019-05-22 2020-11-26 Agios Pharmaceuticals, Inc. Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
US11878049B1 (en) 2019-06-14 2024-01-23 Agios Pharmaceuticals, Inc. Mitapivat therapy and modulators of cytochrome P450
WO2021154987A1 (en) 2020-01-28 2021-08-05 Teva Pharmaceuticals International Gmbh Solid state forms of mitapivat and process for preparation thereof
US20230338283A1 (en) 2020-09-25 2023-10-26 Agios Pharmaceuticals, Inc. Pharmaceutical formulation
MX2023012823A (es) 2021-04-30 2023-12-07 Agios Pharmaceuticals Inc Métodos para ajustar la dosis de mitapivat.
WO2022231627A1 (en) 2021-04-30 2022-11-03 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat for use in treating thalassemia
WO2023154036A1 (en) 2022-02-08 2023-08-17 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat
EP4147700A1 (en) * 2021-09-08 2023-03-15 LQT Therapeutics Inc. N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease
TW202329935A (zh) 2021-11-16 2023-08-01 美商阿吉歐斯製藥公司 用於治療ｍｄｓ相關聯之貧血及其他病況之化合物
WO2024084501A1 (en) 2022-10-17 2024-04-25 Mylan Laboratories Limited Crystalline polymorphs of mitapivat and mitapivat hemisulfate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191496B (ro) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
EP3241554B1 (en) * 2009-06-29 2020-01-29 Agios Pharmaceuticals, Inc. Quinoline-8-sulfonamide derivatives having an anticancer activity
WO2014047167A1 (en) * 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
MA44392B1 (fr) 2015-06-11 2023-10-31 Agios Pharmaceuticals Inc Procédés d'utilisation d'activateurs de la pyruvate kinase

Also Published As

Publication number Publication date
WO2019104134A1 (en) 2019-05-31
CN117551030A (zh) 2024-02-13
ES2959764T3 (es) 2024-02-28
US11254652B2 (en) 2022-02-22
CA3081945A1 (en) 2019-05-31
TW202334115A (zh) 2023-09-01
US20220220093A1 (en) 2022-07-14
LT3713919T (lt) 2023-10-10
TW201930289A (zh) 2019-08-01
CN111372920B (zh) 2023-10-20
JP2021504338A (ja) 2021-02-15
AU2018373122B2 (en) 2023-11-09
BR112020010185A2 (pt) 2021-01-12
PH12020550644A1 (en) 2021-04-26
DK3713919T3 (da) 2023-09-25
PL3713919T3 (pl) 2023-12-27
TWI808108B (zh) 2023-07-11
AU2018373122A1 (en) 2020-05-21
HUE063264T2 (hu) 2024-01-28
EP4285904A2 (en) 2023-12-06
RS64592B1 (sr) 2023-10-31
PT3713919T (pt) 2023-10-26
UA127502C2 (uk) 2023-09-13
SG11202004587XA (en) 2020-06-29
JP7275130B2 (ja) 2023-05-17
IL305343A (en) 2023-10-01
IL274488A (en) 2020-06-30
MX2022009998A (es) 2022-09-19
EP3713919B1 (en) 2023-08-02
AU2024200724A1 (en) 2024-02-22
EP4285904A3 (en) 2023-12-20
JP2023093762A (ja) 2023-07-04
KR20200090787A (ko) 2020-07-29
US20200277279A1 (en) 2020-09-03
FI3713919T3 (fi) 2023-09-29
SI3713919T1 (sl) 2023-10-30
HRP20230931T1 (hr) 2023-11-24
CN111372920A (zh) 2020-07-03
IL274488B1 (en) 2023-09-01
EP3713919A1 (en) 2020-09-30
IL274488B2 (en) 2024-01-01
MX2020005348A (es) 2020-08-13

Similar Documents

Publication Publication Date Title
MD3713919T2 (ro) Forme cristaline de N-(4-(4-(ciclopropilmetil)piperazin-1-carbonil)fenil)chinolin-8-sulfonamidă
WO2019126253A8 (en) Aryl and heteroaryl substituted indole compounds
WO2018195397A3 (en) Indole ahr inhibitors and uses thereof
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
WO2015200680A3 (en) Prmt5 inhibitors and uses thereof
MX2023001876A (es) Derivados de rapamicina.
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MD3319612T2 (ro) Oxisteroli și metode de utilizare a acestora
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
EP4316591A3 (en) Oxysterols and methods of use thereof
CR20200484A (es) COMPUESTOS DE DIHIDROISOQUINOLINONA SUSTITUIDA (Divisional 2016-0574)
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
EA201270535A1 (ru) Пуриновые производные, применимые в качестве ингибиторов hsp90
EA202191519A1 (ru) Модуляторы trex1
EA201991700A1 (ru) Селективные ингибиторы jak1
EA201591397A1 (ru) Хиноксалиноны и дигидрохиноксалиноны как антивирусные средства против респираторно-синцитиального вируса
MX2020006185A (es) Proceso para la preparacion de derivados de quinolina.
WO2016183120A8 (en) Inhibitors of influenza viruses replication
WO2016100302A3 (en) Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones